New diabetes clinical trial: Impact of Sulphonylureas on Neurodevelopmental Outcomes in KCNJ11-related Intermediate Developmental Delay, Epilepsy and Neonatal Diabetes (iDEND) Syndrome
Published on: March 02, 2023 at 11:00AM
Conditions: Neurodevelopmental Disorders; Intellectual Disability; Development Delay; ADHD; Autism Spectrum Disorder; Epilepsy
Intervention: Drug: Sulfonylurea
Sponsors: Royal Devon and Exeter NHS Foundation Trust; University of Chicago; University of Bergen; University of Rome Tor Vergata
Recruiting
https://ift.tt/6XS4gxj
Conditions: Neurodevelopmental Disorders; Intellectual Disability; Development Delay; ADHD; Autism Spectrum Disorder; Epilepsy
Intervention: Drug: Sulfonylurea
Sponsors: Royal Devon and Exeter NHS Foundation Trust; University of Chicago; University of Bergen; University of Rome Tor Vergata
Recruiting
https://ift.tt/6XS4gxj
Comments
Post a Comment